Latest: FDA Approves New Biosimilar for Oncology Treatment
Oncology

Anlotinib/Irinotecan Shows Promise, Durable Responses in ES-SCLC

by Cancer Network
0 Comments
0 Mins
Patients with extensive-stage small cell lung cancer experienced a median PFS and OS of 4.5 months and 7.2 months, respectively, with anlotinib plus irinotecan.
Tags:
Cancer Network
Author

Cancer Network

Previous Post
Talazoparib and enzalutamide improve survival in metastatic castration-resistant prostate cancer
Next Post
Hydroxychloroquine may have a treatment role for chronic inflammatory cardiomyopathy
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago